There is more money than ever fuelling the biotech and MedTech industries, and different kind of investors are entering the stage with more influence than previously thought possible. What are the expectations and specificities of working with angel investors, disease foundations, private equity firms, cross-over funds and family offices? What are the best funding strategies for biotech & MedTech start-ups?

Rémi Soula - Argobio
Anya Roy - Illumina accelerator
Jamie Kemler - Stryker
Stefano Marzario - European Investment Bank

Continue your tour